SP0485 LD 1407 |
Session - 128th Maine Legislature C "A", Filing Number S-245, Sponsored by
|
LR 1195 Item 2 |
|
Bill Tracking, Additional Documents | Chamber Status |
Amend the bill in section 1 in §4320-K in subsection 1 in paragraph A in the 2nd line (page 1, line 7 in L.D.) by striking out the following: " patient" and inserting the following: ' enrollee'
Amend the bill in section 1 in §4320-K in subsection 1 in paragraph B in the 2nd line (page 1, line 10 in L.D.) by striking out the following: " an insurer, health plan" and inserting the following: ' a carrier'
Amend the bill in section 1 in §4320-K in subsection 1 in paragraph D in the 2nd line (page 1, line 19 in L.D.) by striking out the following: " a patient's" and inserting the following: ' an enrollee's'
Amend the bill in section 1 in §4320-K in subsection 1 by striking out all of paragraph E (page 1, lines 22 to 25 in L.D.) and inserting the following:
Amend the bill in section 1 in §4320-K in subsection 1 in paragraph F in the 2nd line (page 1, line 27 in L.D.) by striking out the following: " an insurer or health plan" and inserting the following: ' a carrier'
Amend the bill in section 1 in §4320-K in subsection 2 in paragraph B in subparagraph (1) in the 2nd line (page 1, line 36 in L.D.) by striking out the following: " insurers, health plans" and inserting the following: ' carriers'
Amend the bill in section 1 in §4320-K in subsection 5 in the first line (page 2, line 19 in L.D.) by striking out the following: " insurers, health plans" and inserting the following: ' carriers'
Amend the bill in section 1 in §4320-K by striking out all of subsection 6 (page 2, lines 22 to 38 and page 3, lines 1 to 28 in L.D.) and inserting the following:
(1) The required prescription drug is contraindicated or will likely cause an adverse reaction in or physical or mental harm to the enrollee;
(2) The required prescription drug is expected to be ineffective based on the known clinical characteristics of the enrollee and the known characteristics of the prescription drug regimen;
(3) The enrollee has tried the required prescription drug while under the enrollee's current or previous health insurance or health plan, or another prescription drug in the same pharmacologic class or with the same mechanism of action, and the prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect or an adverse event;
(4) The required prescription drug is not in the best interest of the enrollee, based on medical necessity; or
(5) The enrollee is stable on a prescription drug selected by the enrollee's health care provider for the medical condition under consideration while on a current or previous health insurance or health plan.
(1) A carrier or utilization review organization from requiring an enrollee to try a generic drug, as defined in Title 32, section 13702-A, subsection 14, prior to providing coverage for the equivalent brand-name prescription drug; or
(2) A health care provider from prescribing a prescription drug that is determined to be medically necessary.
Amend the bill in section 1 in §4320-K in subsection 7 in the first line (page 3, line 29 in L.D.) by striking out the following: " shall" and inserting the following: ' may'
Amend the bill in section 2 in the 3rd line (page 3, line 34 in L.D.) by striking out the following: "2018" and inserting the following: '2019'
summary
This amendment does the following.
1. It clarifies that carriers must apply the utilization review standards under current law when acting on a request for a step therapy override exception determination or an appeal of a determination.
2. It replaces certain terminology used in the bill to be consistent with current law.
3. It changes the applicability of the bill’s provisions from January 1, 2018 to January 1, 2019.